AXON - Axovant Sciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.00
+0.08 (+4.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.92
Open1.92
Bid1.86 x 2200
Ask2.02 x 1200
Day's Range1.90 - 2.01
52 Week Range1.02 - 6.59
Volume516,809
Avg. Volume712,820
Market Cap244.162M
Beta (3Y Monthly)0.61
PE Ratio (TTM)N/A
EPS (TTM)-1.52
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.70
Trade prices are not sourced from all markets
  • Associated Press10 days ago

    Axovant: Fiscal 2Q Earnings Snapshot

    The London-based company said it had a loss of 28 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...

  • GlobeNewswire10 days ago

    Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates

    First patient dosed in clinical study of AXO-Lenti-PD, a novel gene therapy for treatment of Parkinson’s diseaseExpanded pipeline of gene therapies with in-licensing of.

  • MarketWatch18 days ago

    Axonics prices IPO at $15 a share

    Axonics Modulation Technologies Inc. priced its initial public offering at $15 a share, the midpoint of its $14 to $16 price range. The medical technology company, which specializes in sacral neuromodulation treatments for overactive bladder and urinary retention among other disorders, sold 8 million shares to raise $120 million. The stock will start trading later Wednesday on Nasdaq under the ticker symbol "AXNX". BofA Merrill Lynch and Morgan Stanley were joint bookrunning mangers on the deal with Wells Fargo acting as lead manager and SunTrust Robinson Humphrey acting as co-manager.

  • GlobeNewswire24 days ago

    Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease

    Axovant Sciences (AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, today announced dosing of the first patient in a clinical study of AXO-Lenti-PD (also known as OXB-102), an investigational gene therapy for the treatment of Parkinson’s disease. AXO-Lenti-PD is a novel gene therapy that enables the expression of a set of three critical enzymes required for end-to-end dopamine synthesis in the brain. AXO-Lenti-PD was administered to the first patient in the study at the Clinical Research Facility affiliated with the National Institute for Health Research (NIHR) and University College London Hospitals (UCLH).

  • GlobeNewswirelast month

    New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?

    Investors need to pay close attention to Axovant Sciences (AXON) stock based on the movements in the options market lately.

  • GlobeNewswirelast month

    Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy

    BASEL, Switzerland, Oct. 09, 2018 -- Axovant Sciences (NASDAQ:AXON), a gene therapy company developing innovative treatments for debilitating neurologic and neuromuscular.

  • See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • GlobeNewswire2 months ago

    Axovant to Present at Two Upcoming Investor Conferences

    BASEL, Switzerland, Sept. 20, 2018-- Axovant Sciences today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September ...

  • PR Newswire2 months ago

    Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases

    BASEL, Switzerland and SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Roivant Sciences today announced the launch of Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases. Respivant will be led by Chief Executive Officer Bill Gerhart, Executive Vice President for Clinical and Regulatory Ahmet Tutuncu, MD, PhD, and Executive Vice President for Development and Manufacturing Pravin Soni, PhD.

  • What Spark Therapeutics’ Valuation Trend Indicates
    Market Realist2 months ago

    What Spark Therapeutics’ Valuation Trend Indicates

    Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.

  • Investors Still Excited about Axovant
    Market Realist2 months ago

    Investors Still Excited about Axovant

    Axovant Sciences (AXON) is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel therapies in neurology and psychiatry. Its product candidates are targeted at neurological diseases, including Parkinson’s disease, oculopharyngeal muscular dystrophy, Lewy body dementia, and other indications. The former is a potential one-time treatment for Parkinson’s disease, and the latter is a potential one-time treatment for oculopharyngeal muscular dystrophy.

  • Analyzing Axovant Sciences’ Valuation Metrics
    Market Realist2 months ago

    Analyzing Axovant Sciences’ Valuation Metrics

    In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given the stock a “buy” rating, and five have given it a “hold.” The mean rating for Axovant stock is 2.71 with a target price of $4.70, implying an upside potential of 129.3% over its trading price of $2.05 on September 11.

  • Audentes Therapeutics’ Promising Product Pipeline
    Market Realist2 months ago

    Audentes Therapeutics’ Promising Product Pipeline

    Gene therapy involves repairing or replacing disease-causing genes. Investor interest in gene therapy stocks has remained buoyant throughout 2018. According to Allied Market Research, the gene therapy market is expected to grow at a 33.3% CAGR (compound annual growth rate) to $4.4 billion by 2023.

  • See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • GlobeNewswire3 months ago

    Axovant to Present at Upcoming Investor Conferences

    BASEL, Switzerland, Aug. 29, 2018-- Axovant Sciences today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor conferences. Dr Cheruvu will present a ...

  • See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Stocks to Watch: Axovant Sciences and Gevo

    NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Gevo and Axovant Sciences had something in common on Tuesday. Axovant Sciences Ltd. was up 14.43% at the close on Tuesday on about 1.5 million shares traded.

  • See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Puma Biotechnology: Recent Developments and Recommendations
    Market Realist3 months ago

    Puma Biotechnology: Recent Developments and Recommendations

    In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.

  • Associated Press3 months ago

    Axovant: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the London-based company said it had a loss of 48 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.08. A year ago, they were trading at $22.89. _____ ...

  • See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
    Markit4 months ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
    Zacks4 months ago

    Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock

    Investors in Axovant Sciences (AXON) need to pay close attention to the stock based on moves in the options market lately.

  • 3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
    Zacks4 months ago

    3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018

    Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.